primary prevention of coeliac disease - Associazione Italiana ...

94
INDEX
low-molecular weight, 76
functional properties of, 76
specific response
in children, 13
in adults, 14
toxicity, 89
-specific memory T cells, 20
Glutenin, 1, 4, 27, 75-77, 89-90
Gut barrier, 91
H
HLA genes - see genetic predisposition
I
Immunotherapy, 83-88, 90
Infant feeding, 45, 52-54
Insulin dependent diabetes mellitus (IDDM)
risk, 44
Intestinal mucosa, 91
Intraepithelial lymphocytes (IELs), 6, 67
γδ, 6
M
Mucosal immune
response
control of, 65-69
system, 63, 66
tolerance, 69-70
N
Non-HLA genes, 32, 44
O
Oats, 27, 53
Organ culture, 6, 28, 84-85
P
Pathophysiology of coeliac disease, 6, 43,
69, 90
Aetiology, 1, 17, 43
multifactorial, 51
Prevalence of coeliac disease, 1, 33
in the general pediatric population, 1, 36
in the Saharawi, 33, 37
in the Sardinians, 37
in family members, 1, 43
Primary prevention, 43, 56, 89
R
Risk factors, 31-32
associated, 51
component causal, 51
necessary causal, 51
contributing, 50
infections, 50
socio-economic background, 50
Rye, 1, 23-24, 27, 43, 53, 75
S
Saharawi population, 33-37
Small intestinal biopsy, 33, 37
Susceptibility haplotype, 37
T
T cell, 2-4, 7, 62, 64. 90
activation, 6, 13, 17, 62, 89-90
antigen specific, 18
CD4, 17-19, 21
CD4+ TCRαβ, 2-3, 6-7
CD8, 17
clones, 5, 14
intestinal, 19, 22
peripheral blood, 19
delayed-type hypersensitivity, 61
DQ2-restricted, 90
epitope, 7, 17, 19
dominant, 24
gliadin-specific, 19
hierarchy, 21
gluten reactive, 3
helper, 67
gliadin-specific, 21
receptor, 17
regulatory, 63, 68, 85
response, 14, 89-90
suppressor, 63
Th1, 83
tolerance, 68
TGF-β, 68
Tissue transglutaminase (tTG), 4, 6-7, 13,
19, 37, 90
activity, 4-5
antibodies, 6-7
Tolerance, 61-63, 90
central, 62
immune, 56, 62
mucosal immune, 69, 86-87
oral, 5, 7, 13, 44, 46, 48, 64-65, 67-68, 70
experimental models of, 65
peripheral, 62
Treated coeliac disease, 18
Twins, 1, 31, 43
V
Vaccine, 17, 56, 65, 90